ESR1 and breast carcinoma: In mammary carcinomas, MB was found to be expressed in around 40% of invasive ductal carcinomas where it positively correlates with a higher degree of tumor cell differentiation (luminal subtype), estrogen receptor positivity (ER+), and a significantly better prognostic outcome in ER+ or ER– breast cancer patients [8].